All In Biotech

Drug Trial Radar · NCT07842445

Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.

A Phase 1a/1b, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of GNTbm 38 in Solid Tumors and Relapsed/Refractory Peripheral T-Cell Lymphoma.

Last checked: Nov 20, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Feb 28, 2029

Study completion Jun 30, 2029

Sponsor

Sponsor type
Industry
First posted
Sep 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of GNTbm-38 in adult patients with advanced solid tumors and R/R PTCL.

Conditions

  • Solid Tumor (Phase I)
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Interventions

  • GNTbm-38Drug

    Phase 1a is the dose escalation phase to firstly determine the MTD of patients with solid tumor. Once MTD for solid tumor patients has been established, the next lower dose of this MTD will serve as an initial dose to determine the MTD for patients with R/R PTCL. Phase 1b is the dose expansion phase to evaluate the safety, tolerability, and efficacy of GNTbm-38 in R/R PTCL patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1a: The MTD and DLT of GNTbm-38Time frame: At the end of Cycle 1 (each cycle is 28 days)
  2. Phase Ia: To define the safety and tolerabilityTime frame: At the end of Cycle 1 (each cycle is 28 days)
  3. Phase Ib: To evaluate the efficacy of GNTbm-38 in patients with R/R PTCL.Time frame: At the end of Cycle 1 (each cycle is 28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.